Initiation of stock buyback program

On February 14, 2018, Novozymes will initiate a stock buyback program as announced in Company Announcement No. 1, of February 7, 2018. Under the program Novozymes will buy back B shares worth up to DKK 2 billion in total during the remainder of 2018, corresponding to around 6.7 million B shares at the current share price. The program is contingent upon no major strategic initiatives being decided upon that will require a significant amount of capital, for example a major acquisition.

The stock acquired within the program will be used to reduce the common stock and to meet obligations arising from stock-based incentive programs. The cancelation of stock will take place after the program is finished and will be subject to approval at the Annual Shareholders’ Meeting.

To ensure there is no negative impact on the free float of Novozymes’ stock capital, Novozymes’ principal shareholder, Novo A/S, has informed Novozymes that it has the intention to reduce its relative holding of B shares so that it will continue to hold around 25.5% of the total stock capital following Novozymes’ cancelation of stock because of the stock buyback program.

The maximum number of shares to be purchased by the company per daily market session will be equivalent to no more than 25% of the average volume of shares in the company traded on NASDAQ OMX Copenhagen during the preceding 20 business days. The program will run in accordance with the commission regulation (EU) 596/2014 of 16 April 2014, also known as the “Market Abuse Regulation”, and commission regulation (EU) 1052/2016 of 8 March 2016.